期刊文献+

斑蝥酸钠维生素B_6对人肝星状细胞增殖的影响及其机制 被引量:4

Influence and mechanism of disodium cantharidinate and vitamin B_6 injection on the proliferation of human hepatic stellate cells
下载PDF
导出
摘要 目的探讨斑蝥酸钠维生素B6注射液对人肝星状细胞LX-2增殖活化的影响及其机制。方法培养人肝星状细胞LX-2,将其分为3个观察组(斑蝥酸钠维生素B6的浓度分别为1、5、10μg/mL)和1个空白对照组;培养24、48、72 h后,采用MTT法检测细胞增殖活性,采用荧光定量PCR方法检测Ⅰ型胶原、Ⅲ型胶原、转化生长因子β1基因表达变化。结果与空白对照组比较,观察组人肝星状细胞LX-2增殖活化被显著抑制(P均<0.05),Ⅰ型胶原、Ⅲ型胶原、转化生长因子β1mRNA表达下降(P均<0.05)。结论斑蝥酸钠维生素B6可以抑制人肝星状细胞LX-2增殖活化,其机制可能与其抑制、转化生长因子β1信号通路有关。 Objective To study the influence and mechanism of disodium cantharidinate and vitamin B6 injection on the proliferation and activation of human hepatic stellate cells LX-2. Methods The human hepatic stellate cells LX-2 were cultured and divided into 4 groups : the control group, three experimental groups treated with different concentrations of disodium cantharidinate ( 1, 5 and 10 p.g/mL, respectively). The proliferative activities of LX-2 were detected by MTF after 24 h, 48 h and 72 h. The expression changes of COL Ⅰ , COL Ⅲ and TGF-131 mRNA in LX-2 cells were determined by FQ-PCR; and the expression changes of COL Ⅰ , COL Ⅲ and TGF-β1 protein in LX-2 cells were determined by Western blot. Results Compared with the control group, the proliferation and activation of human hepatic stellate cells LX-2 in the three experimental groups were significantly inhibited ( all P 〈 0.05 ) , and the expression of COL Ⅰ , COL Ⅲ and TGF-β1 mRNA in LX-2 cells were decreased ( all P 〈 0.05 ). Conclusion Disodium cantharidinate and vitamin B6 injection can inhibit the proliferation and activation of LX-2 cell line, whose mechanism might be correlated with the inhibition of TGF-β1 signal pathway.
出处 《山东医药》 CAS 2013年第29期22-24,共3页 Shandong Medical Journal
基金 河北省医学科学研究重点课题计划项目(20110558)
关键词 人肝星状细胞 斑蝥酸钠维生素B6 细胞增殖 human hepatic stellate cells disodium cantharidinate and vitamin B6 cell proliferation
  • 相关文献

参考文献9

二级参考文献22

  • 1范跃祖,傅锦业,赵泽明,陈春球.去甲斑蝥素对人胆囊癌GBC-SD细胞系生长的影响及其机制探讨[J].肿瘤,2004,24(4):358-361. 被引量:8
  • 2桂尤胜,曹献英,陈筠.斑蝥酸钠体外诱导肝癌细胞凋亡的实验研究[J].武汉大学学报(医学版),2004,25(5):493-496. 被引量:32
  • 3孙燕 周际昌.临床肿瘤内科手册(第3版)[M].北京:人民卫生出版社,1996.98.
  • 4Jemal A,Siegel R,Xu J,et al.Cancer statistics 2010[J].CACancer J Clin,2010,60(5):277-300.
  • 5Rauth R,Kahl S,Boechzelt H,et al.Molecular biology ofcantharidin in cancer cells[J].Chin Med,2007,4:2-8.
  • 6Prend ergast GC,Jaffee EM.Cancer immumologists and cancer biologists why we did not talk then but need to now[J].Cancer Res,2007,(67):3500.
  • 7Miller AB,Hoogstraten B.Staquet M,et al.Reporting resuIts of cancer treatment.Cancer 1981;47(1):207~214.
  • 8Pizza G, Severini G, Menniti D, et al. Tumor regression after interalesional injection of interleukin 2 (IL-2) in bladder cancer.Int J cancer 1984;34(3):359-367.
  • 9Huland E, Huland H.Local continous high dose interleukin-2:a new therapeutic model for the treatment of advanced bladder cancer. Cancer Res 1989;49(19):5469-5474.
  • 10王泽民.当代结构药物全集[M].北京:北京科学技术出版社,1993.2125.

共引文献73

同被引文献29

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部